BR112022012081A2 - Método para tratar câncer, kit, e, uso de uma combinação terapêutica - Google Patents

Método para tratar câncer, kit, e, uso de uma combinação terapêutica

Info

Publication number
BR112022012081A2
BR112022012081A2 BR112022012081A BR112022012081A BR112022012081A2 BR 112022012081 A2 BR112022012081 A2 BR 112022012081A2 BR 112022012081 A BR112022012081 A BR 112022012081A BR 112022012081 A BR112022012081 A BR 112022012081A BR 112022012081 A2 BR112022012081 A2 BR 112022012081A2
Authority
BR
Brazil
Prior art keywords
kit
therapeutic combination
treat cancer
cancer
antagonist
Prior art date
Application number
BR112022012081A
Other languages
English (en)
Inventor
E Brandish Philip
A Altura Rachel
Piperdi Bilal
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112022012081A2 publication Critical patent/BR112022012081A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

MÉTODO PARA TRATAR CÂNCER, KIT, E, USO DE UMA COMBINAÇÃO TERAPÊUTICA. São aqui providos métodos para tratar câncer (por exemplo, NSCLC), que compreende administrar a um paciente humano com necessidade do mesmo: (a) um antagonista de PD-1; (b) um antagonista de ILT4; e (c) um ou mais agentes quimioterapêuticos. Também são providos composições farmacêuticas e kits contendo tais agentes para o tratamento de câncer.
BR112022012081A 2019-12-20 2020-12-16 Método para tratar câncer, kit, e, uso de uma combinação terapêutica BR112022012081A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951357P 2019-12-20 2019-12-20
PCT/US2020/065208 WO2021126906A1 (en) 2019-12-20 2020-12-16 Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
BR112022012081A2 true BR112022012081A2 (pt) 2022-08-30

Family

ID=76476667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012081A BR112022012081A2 (pt) 2019-12-20 2020-12-16 Método para tratar câncer, kit, e, uso de uma combinação terapêutica

Country Status (10)

Country Link
US (1) US20230050449A1 (pt)
EP (1) EP4076521A4 (pt)
JP (1) JP2023510132A (pt)
KR (1) KR20220123017A (pt)
CN (1) CN115087461A (pt)
AU (1) AU2020408678A1 (pt)
BR (1) BR112022012081A2 (pt)
CA (1) CA3162311A1 (pt)
MX (1) MX2022007516A (pt)
WO (1) WO2021126906A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023003790A1 (en) * 2021-07-20 2023-01-26 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016026559A8 (pt) * 2014-05-15 2021-07-13 Bristol Myers Squibb Co uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
JP2021513541A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体によるがんの処置方法
JP2023510199A (ja) * 2020-01-02 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよびレンバチニブまたはその塩を使用する組合せ癌治療

Also Published As

Publication number Publication date
WO2021126906A1 (en) 2021-06-24
US20230050449A1 (en) 2023-02-16
CN115087461A (zh) 2022-09-20
JP2023510132A (ja) 2023-03-13
AU2020408678A1 (en) 2022-06-23
EP4076521A4 (en) 2024-01-24
MX2022007516A (es) 2022-07-05
KR20220123017A (ko) 2022-09-05
EP4076521A1 (en) 2022-10-26
CA3162311A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
MX2023006488A (es) Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial.
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
BR112022026094A2 (pt) Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit
BR112022026086A2 (pt) Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica